Table I.
Baseline characteristics of patients included in the analysis along with the division into patients receiving ADA or IFX
| Parameter | All | ADA | IFX | P-value |
|---|---|---|---|---|
| N | 52 | 29 | 23 | – |
| Age, median (IQR) | 33 (26–42.5) | 33 (25–54) | 32 (26–39) | 0.912 |
| Age at diagnosis, median (IQR) | 27 (20–39.5) | 21 (18–26) | 40 (29–45) | 0.555 |
| Women, n (%) | 23 (44.23) | 14 (48.28) | 9 (39.13) | 0.51 |
| Other chronic diseases, n (%) | 19 (36.54) | 12 (41.38) | 7 (30.43) | 0.416 |
| Previous surgical procedures, n (%) | 16 (30.77) | 9 (31.03) | 7 (30.43) | 0.963 |
| Use of immunomodulators, n (%) | 30 (57.69) | 19 (65.52) | 11 (47.83) | 0.2 |
ADA – adalimumab, IFX – infliximab, IQR – interquartile range, n – number of participants.